Motoki et al. studied the effect of PPAR-γ agonists on the aortic wall in patients with AA and found that it may prevent or delay the progression of the aneurysm in patients via decreasing the expression of MMP-9 and TNF-α in the wall of the AA (84). Here, MMP9 is linked to aneurysm.